Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus
Phase 4
Completed
- Conditions
- PROTEINURIAHypertensionType 2 Diabetes
- Registration Number
- NCT00241085
- Lead Sponsor
- Novartis
- Brief Summary
This is a study of whether valsartan affects levels of proteinuria in patients with type 2 diabetes and hypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 392
Inclusion Criteria
- Mild to moderate hypertension, Mild renal dysfunction, Type 2 diabetes,
Exclusion Criteria
Pregnant or breast feeding, Type 1 diabetes
Other protocol criteria apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in urinary protein excretion after 30 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in circulating markers of blood vessel inflammation, insulin resistance, serum creatinine, diabetic control, and proportion of patients who return to normalization of protein excretion after 30 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie valsartan's effect on reducing proteinuria in type 2 diabetic patients with hypertension?
How does valsartan compare to other ARBs like losartan in managing proteinuria in hypertensive type 2 diabetes patients?
Which biomarkers, such as ACE gene polymorphisms, predict valsartan response in proteinuria reduction among type 2 diabetes patients?
What are the adverse event profiles of valsartan versus standard antihypertensives in diabetic nephropathy patients?
What combination therapies with valsartan enhance proteinuria reduction in type 2 diabetes and hypertension?